XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
EARNINGS (LOSS) PER SHARE AND STOCKHOLDERS’ EQUITY
 9 Months Ended
Dec. 31, 2023
EARNINGS (LOSS) PER SHARE AND STOCKHOLDERS’ EQUITY  
EARNINGS (LOSS) PER SHARE AND STOCKHOLDERS’ EQUITY EARNINGS (LOSS) PER SHARE AND STOCKHOLDERS’ EQUITY:
 
Earnings (Loss) Per Share
 
A reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share is shown below (in thousands, except per share amounts):
 
For the three months endedFor the nine months ended
December 31,December 31,
2023202220232022
Basic earnings (loss) per share:
Net earnings (loss) from continuing operations$13,379 $(30,520)$16,269 $(88,174)
Earnings from discontinued operations, net of tax598 836 985 836 
Net earnings (loss)$13,977 $(29,684)$17,254 $(87,338)
Basic weighted-average shares outstanding65,961 64,784 66,247 66,761 
Continuing operations$0.20 $(0.47)$0.25 $(1.32)
Discontinued operations0.01 0.01 0.01 0.01 
Basic earnings (loss) per share$0.21 $(0.46)$0.26 $(1.31)
Diluted earnings (loss) per share:
Basic weighted-average shares outstanding65,961 64,784 66,247 66,761 
Dilutive effect of common stock options and restricted stock units as computed under the treasury stock method (1)1,982 — 1,486 — 
Diluted weighted-average shares outstanding67,943 64,784 67,733 66,761 
Continuing operations$0.20 $(0.47)$0.24 $(1.32)
Discontinued operations0.01 0.01 0.01 0.01 
Diluted earnings (loss) per share$0.21 $(0.46)$0.25 $(1.31)

(1) The number of common stock options and restricted stock units as computed under the treasury stock method that would have otherwise been dilutive but are excluded from the table above because their effect would have been anti-dilutive due to the net loss position of the Company was 0.5 million and 0.6 million in the three and nine months ended December 31, 2022.

Restricted stock units that were outstanding during the periods presented but were not included in the computation of diluted loss per share because their effect would have been anti-dilutive (other than due to the net loss position of the Company) are shown below (shares in thousands):
 
For the three months endedFor the nine months ended
December 31,December 31,
2023202220232022
Number of shares underlying restricted stock units1,046 6,215 1,065 2,980 
 
Stockholders’ Equity

On December 20, 2022, the Company's board of directors approved an amendment to the existing common stock repurchase program, which was initially adopted in 2011. The amendment authorized an additional $100.0 million in share repurchases, increasing the total amount authorized for repurchase under the common stock repurchase program to $1.1 billion. In addition, it extended the common stock repurchase program duration through December 31, 2024.

During the nine months ended December 31, 2023, the Company repurchased 1.7 million shares of its common stock for $45.3 million under the modified common stock repurchase program.  Through December 31, 2023, the Company had repurchased a total of 37.3 million shares of its common stock for $927.5 million under the program, leaving remaining capacity of $172.5 million.
 
Accumulated other comprehensive income balances of $4.5 million and $5.7 million at December 31, 2023 and March 31, 2023, respectively, reflect accumulated foreign currency translation adjustments.